Treatment study for enterococcus faecalis bloodstream infection
Part of Infections clinical trials.
This trial looks at how well certain penicillin-type antibiotics work for treating a bloodstream infection caused by a bacterium called Enterococcus faecalis. It may help doctors know which treatment is best for patients with this infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have had a positive blood test for Enterococcus faecalis between January 2017 and December 2023
- You were treated with penicillin for 7 days or more
- Your treatment included amoxicillin or piperacillin-tazobactam (penicillin drugs)
- The bacterium was not resistant to amoxicillin
- You did not have another serious infection (endocarditis) in the first 7 days of treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gathers information about blood infections to better understand them and improve care. It may help by providing detailed data on your specific infection.
This study looks at new ways to fight antibiotic-resistant bacteria in people with certain common infections. It may help by testing approaches tailored to the specific germs found in your urine, lungs, or deeper infections.
This study tests a careful antibiotic-use program for patients with a bloodstream infection caused by a group of bacteria called Enterobacterales. The goal is to use the right antibiotics for the right amount of time. It may help you get better treatment with fewer side effects.
This study looks at whether using two or more antibiotics together works better than one alone for a specific type of blood infection caused by Enterococcus faecalis bacteria. The goal is to find the safest and most effective way to treat this infection and improve outcomes for patients.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
This trial tests a new antibiotic combination, cefepime/enmetazobactam, against standard therapy for people with complicated urinary tract infections that have spread to the bloodstream. It aims to see if the new drug works better and is safe.
Hear when a new Enterococcus Faecalis Bacteremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.